Regentis Biomaterials Ltd. (RGNT) Comparison with companies in other sectors?

Regentis Biomaterials Ltd. has a share price of 3.94M. You can analyze Regentis Biomaterials Ltd. (RGNT) competitors across different market sectors through stock heatmaps.

What are RGNT's NET and operating margins?

Regentis Biomaterials Ltd. (RGNT) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does RGNT's earnings per share (EPS) trend reflect its financial momentum?

Regentis Biomaterials Ltd. (RGNT) EPS is -1.10 (If EPS value is positive, then "signals consistent profit growth" if Negative then "signals consistent loss"). This metric is also critical in assessing valuation metrics like the P/E ratio for Regentis Biomaterials Ltd. is -3.71, and the company's ability to reinvest or distribute profits.

What does a high ROE mean for Regentis Biomaterials Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Regentis Biomaterials Ltd. like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Regentis Biomaterials Ltd.

RGNT•AMEX

Healthcare

Medical - Instruments & Supplies

$4.15

$0.24(6.14%)

U.S. Market is Open • 12:42

Regentis Biomaterials Ltd. Fundamental Analysis

Regentis Biomaterials Ltd. (RGNT) shows weak financial fundamentals with a PE ratio of -3.71, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze RGNT's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze RGNT's fundamental strength across five key dimensions:

Efficiency Score

Weak

RGNT struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Moderate

RGNT shows balanced valuation metrics.

PE < 25

-3.71

PEG Ratio < 2

N/A

Growth Score

Weak

RGNT faces weak or negative growth trends.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

RGNT carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

RGNT struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is RGNT Expensive or Cheap?

P/E Ratio

RGNT trades at -3.71 times earnings. This suggests potential undervaluation.

-3.71

How Well Does RGNT Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How RGNT Stacks Against Its Sector Peers

Metric	RGNT Value	Sector Average	Performance
P/E Ratio	N/A	29.43	N/A
ROE	N/A	800.00%	N/A
Net Margin	N/A	-20145.00% (disorted)	N/A
Debt/Equity	N/A	0.30	N/A
Current Ratio	N/A	4.64	N/A
ROA	N/A	-17936.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Regentis Biomaterials Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Regentis Biomaterials Ltd. Fundamental Analysis

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is RGNT Expensive or Cheap?

How Well Does RGNT Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How RGNT Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

Regentis Biomaterials Ltd. (RGNT) Comparison with companies in other sectors?

What are RGNT's NET and operating margins?

In what way does RGNT's earnings per share (EPS) trend reflect its financial momentum?

What does a high ROE mean for Regentis Biomaterials Ltd.?

How do I know if AAPL is overvalued or undervalued?